Frontlight ResearchEarly access
CompletedNo phase
An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Austin, Boston, Columbus, Fort Worth, Houston, Kansas City, Lawrenceville, Long Beach, Los Angeles, Marietta, Memphis, Miami, Newark, Philadelphia, Plantation, Richmond, San Francisco, Smyrna, and St Louis, United StatesSee the 19 sitesAlso in 5 other countries, 25 sites
- Trial code
- Status
- Completed
- People taking part
- 537 people enrolled
- Started
- 9 Jun 2021
- Ended
- 14 Mar 2024
- Type of study
- Observational
- Treatments tested
- Blood sampling
- Anogenital lesion swab collection
- Record updated
- 7 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Man or woman ≥18 years old
- Written informed consent obtained from the patient prior to performance of any study-specific procedure
- History of at least one episode of HSV-2 genital herpes lesions in the 12 months preceding the screening, and seropositive for HSV-2 as determined by Western blot OR PCR-positive for HSV-2 (newly diagnosed patients)
- Patients who are medically stable in the opinion of the investigator
- Patients who, in the opinion of the investigator, are able to understand and comply with the study requirements (attend regular telephone calls/study site visits/home visits/self-completion of questionnaires, self-swabbing)
- Seronegative for HIV, as determined by laboratory testing. Patients documented to be positive to HIV will not be eligible for study participation
Who cannot take part
- Prior receipt of a vaccine or candidate vaccine containing HSV antigens
- Other genital tract disorders or sexually transmitted diseases that may interfere with the assessment of the study (as per investigator's judgement)
- Immunocompromised patients, as per medical history and investigator judgement
Where in United States
Also in 5 other countries, 25 sites
- Austin, TexasHospital not named in the registry
- Boston, MassachusettsHospital not named in the registry
- Columbus, OhioHospital not named in the registry
- Fort Worth, TexasHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Kansas City, MissouriHospital not named in the registry
- Lawrenceville, GeorgiaHospital not named in the registry
- Long Beach, CaliforniaHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Marietta, GeorgiaHospital not named in the registry
- Memphis, TennesseeHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Newark, DelawareHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Plantation, FloridaHospital not named in the registry
- Richmond, VirginiaHospital not named in the registry
- San Francisco, CaliforniaHospital not named in the registry
- Smyrna, GeorgiaHospital not named in the registry
- St Louis, MissouriHospital not named in the registry
About the trial
What the trial wants to find out
The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe.
Read full original descriptionShow less
More specifically, the study aims to evaluate patient-reported outcome and quality-of-life endpoints as well as the performance study procedures in a decentralised setting. Ultimately, this study will allow generating additional real-world evidence (RWE) on patterns of recurrences and other key parameters.
The group in the trial
- Overall Study Group
Patients aged 18 years old or above, with HSV-2 genital herpes, who are recruited in specific community settings in the United States and in Europe.
Treatment: Blood sampling and Anogenital lesion swab collection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Descriptive, Prospective, Multi-country, Multicentre Study to Assess Performance of Genital Herpes Simplex Virus-2 (HSV-2) Related Disease Endpoints Based on Patient-reported Health Outcomes, Self-swabbing Collected Via Decentralised Approach in Patients ≥ 18 Years of Age in the United States and Europe.
- Record updated
- 7 March 2025